doi:10.1016/j.obpill.2025.100162
Additionally, semaglutide slows the emptying of your stomach, enhancing your sense of fullness and helping you eat less frequently
As with other GLP-1 medicines, people with: A history of severe gastrointestinal disease Pancreatitis Significant kidney or liver issues should only use GLP-1 treatments under close clinical monitoring
For the first time, the guidelines clearly prioritize real, minimally processed food over packaged convenience
Despite the encouraging results of GLP-1/glucagon co-agonism in experimental models, different GLP-1 and glucagon co-agonists have shown various levels of efficacy and tolerability in people with obesity and/or T2D, in early phase clinical trials, which may be explained by the different ratio of GLP-1 to glucagon activity between the different molecules [65]
There are several reasons for women dropping GLP-1 weight loss drugs, and they often overlap: Side effects
